MiRNA Effects on Gut Homeostasis: Therapeutic Implications for Inflammatory Bowel Disease
Overview
Authors
Affiliations
Inflammatory bowel disease (IBD) spans a range of chronic conditions affecting the gastrointestinal (GI) tract, which are marked by intermittent flare-ups and remissions. IBD results from microbial dysbiosis or a defective mucosal barrier in the gut that triggers an inappropriate immune response in a genetically susceptible person, altering the immune-microbiome axis. In this review, we discuss the regulatory roles of miRNAs, small noncoding RNAs with gene regulatory functions, in the stability and maintenance of the gut immune-microbiome axis, and detail the challenges and recent advances in the use of miRNAs as putative therapeutic agents for treating IBD.
Chronic Gastrointestinal Disorders and miRNA-Associated Disease: An Up-to-Date.
Giammona A, Galuzzi B, Imperia E, Gervasoni C, Remedia S, Restaneo L Int J Mol Sci. 2025; 26(1.
PMID: 39796266 PMC: 11720538. DOI: 10.3390/ijms26010413.
Brusnic O, Olga B, Boicean A, Adrian B, Fleaca S, Sorin-Radu F Nutrients. 2025; 16(24).
PMID: 39771031 PMC: 11676862. DOI: 10.3390/nu16244411.
Probiotics Exert Gut Immunomodulatory Effects by Regulating the Expression of Host miRNAs.
Li W, Zeng Y, Zhong J, Hu Y, Xiong X, Zhou Y Probiotics Antimicrob Proteins. 2025; .
PMID: 39754704 DOI: 10.1007/s12602-024-10443-9.
MicroRNA signatures in the pathogenesis and therapy of inflammatory bowel disease.
Ramadan Y, Kamel A, Medhat M, Hetta H Clin Exp Med. 2024; 24(1):217.
PMID: 39259390 PMC: 11390904. DOI: 10.1007/s10238-024-01476-z.
Apolipoprotein A-I: Potential Protection Against Intestinal Injury Induced by Dietary Lipid.
Wang J, Yu S, Huang G, Yu Y, Li Y J Inflamm Res. 2024; 17:5711-5721.
PMID: 39219814 PMC: 11366247. DOI: 10.2147/JIR.S468842.